Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly. The launch of several new therapies and new formulations of key brands will drive market growth, but growth will be offset with the genericization of several key PD therapies, including Boehringer Ingelheim's Mirapex (pramipexole) and GlaxoSmithKline's Requip (ropinirole). We analyze the impact of genericization on the reimbursement of key brands and survey pharmacy directors on how they expect to reimburse PD therapies currently in Phase III development.
Using tiering and restrictions data from Fingertip Formulary, as well as insight from 51 pharmacy directors, this report determines the key trends in reimbursement of Parkinson's Disease treatments, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition.